Waldenström's Macroglobulinemia and Monoclonal Gammopathies

Diagnostic Criteria

• The European Society for Medical Oncology (ESMO) guidelines include diagnostic criteria for Waldenström's Macroglobulinemia (WM), such as monoclonal IgM protein, bone marrow infiltration with lymphoplasmacytic cells, and symptoms related to tumor infiltration or IgM production 1
• Monoclonal gammopathy of undetermined significance (MGUS) is characterized by serum monoclonal protein <3 g/dL, <10% clonal bone marrow plasma cells, and absence of end-organ damage (hypercalcemia, renal insufficiency, anemia, bone lesions) 2
• Smoldering multiple myeloma (SMM) is characterized by serum monoclonal protein ≥3 g/dL and/or ≥10% clonal bone marrow plasma cells, and absence of end-organ damage 2
• Symptomatic multiple myeloma requires ≥10% clonal bone marrow plasma cells, presence of serum/urinary monoclonal protein, and evidence of end-organ damage 2
• Lymphoplasmacytic lymphoma, also known as Waldenström's macroglobulinemia, is characterized by bone marrow infiltration with IgM-producing clonal cells, according to the National Comprehensive Cancer Network and the American College of Hematology 3, 4

Risk Stratification

• The average risk of progression from MGUS to multiple myeloma or other lymphoproliferative disorders is 1% per year, with a 20-year absolute risk of progression based on risk factors, as follows:

  Risk Group	Risk Factors	20-year Absolute Risk
  Low	None	1.65%
  Low-intermediate	Any 1 factor	5.42%
  High-intermediate	Any 2 factors	10.13%
  High	All 3 factors	20.85%

• High protein monoclonal (M-protein) markers indicate an increased risk of progression to malignant plasma cell disorders and potential organ damage from toxic M-proteins, requiring risk-stratified monitoring and possible intervention, as supported by the American College of Hematology 6

Clinical Manifestations and Complications

• M-proteins can cause significant morbidity through renal diseases, such as monoclonal immunoglobulin deposition disease (MIDD), light-chain proximal tubulopathy, immunotactoid glomerulopathy, and proliferative glomerulonephritis with monoclonal Ig deposits, as reported by the American Society of Clinical Oncology 6
• M-proteins can also cause metabolic disturbances, such as hyperlipidemia, xanthomas, and atherosclerosis, as well as neurological disorders, such as hyperviscosity syndrome and neuropathies 6
• Bone disease, such as osteoporosis and osteolytic lesions, can also be caused by M-proteins, as supported by the National Comprehensive Cancer Network 6
• Hyperviscosity syndrome can occur when IgM levels exceed 60 g/L, leading to symptoms such as headaches, blurred vision, and neurological deficits, as reported by the American Society of Clinical Oncology 3, 7

Diagnostic Evaluation

• Complete blood count with differential, serum chemistry, serum protein electrophoresis and immunofixation, quantitative immunoglobulins, serum free light chain assay, and 24-hour urine protein electrophoresis and immunofixation are recommended for diagnosis and monitoring, as suggested by the American College of Hematology 2
• IgG MGUS does not require routine bone marrow examination if serum M-protein ≤15 g/L and no end-organ damage, but IgA and IgM MGUS require bone marrow examination regardless of M-protein level, as recommended by the Haematologica guidelines 6
• Low-dose whole-body CT is recommended for patients with MGUS, except for those with IgG M-protein ≤15 g/L or IgA M-protein ≤10 g/L without bone pain, as supported by the European Society for Medical Oncology 6
• Serum free light chain assay should be evaluated to assess the kappa/lambda ratio, as recommended by the International Myeloma Society 1

Treatment and Follow-up

• Treatment is indicated when progression to symptomatic multiple myeloma or other lymphoproliferative disorder occurs, or when M-protein-related organ damage develops, as supported by the National Comprehensive Cancer Network 6
• Bortezomib-based regimens are preferred for renal disorders, while lenalidomide-based regimens are preferred for patients with neuropathy, as recommended by the European Society for Medical Oncology 6
• The American College of Hematology recommends treatment indications for Waldenström's macroglobulinemia, including symptomatic hyperviscosity, anemia, thrombocytiania, B symptoms, and symptomatic organomegaly or lymphadenopathy 3, 7
• Low-risk MGUS requires follow-up every 2-3 years, while intermediate and high-risk MGUS requires follow-up every 6-12 months, as recommended by the International Myeloma Working Group 5
• Evolving MGUS (increasing M-protein) requires follow-up every 3-4 months if M-protein reaches ≥30 g/L and fulfills SMM criteria, as suggested by the American Society of Clinical Oncology 6
• The ESMO guidelines categorize treatment response in WM based on reduction in IgM levels, with categories including complete response (Normalization of IgM), very good partial response (≥90% reduction in IgM), partial response (≥50% but <90% reduction in IgM), and minor response (≥25% but <50% reduction in IgM) 1
• For patients with WM, the ESMO guidelines recommend follow-up to include history, physical examination, blood count, routine chemistry, quantification of IgM every 3 months for 2 years, and minimal adequate radiological examinations every 6 months for 2 years 1